losses and premium valuation clash
ALMR is promising long-term in proteomics-enabled early disease detection, but I’m bearish on the stock as an investment right now because it’s still unprofitable (nearly $30M net loss) with limited margin for error at roughly a 21 price-to-sales multiple and a $1.6B+ market cap.
Near-$30M net losses paired with a 21x price-to-sales multiple and $1.6B+ market cap leave little margin for execution errors in early-stage proteomics diagnostics. The promising long-term science does not offset current profitability risk.
"7 Stocks Cathie Wood is Buying Right Now!"